🇺🇸

US SEC Filing Intelligence

· daily

All NASA Contracts — March 06, 2026

NASA's four historical contracts totaling $3.41B obligations (84% to Lockheed Martin) highlight trusted incumbents in space vehicle components and support, with bullish signals on Lockheed and Hamilton Sundstrand amid $268M unexercised options. Zero outlays and expired performance periods (2004-2013) across all signal data lags or completion, limiting near-term cash flow relevance. Investors gain insight into NASA's cost-plus preference for non-competitive awards to space primes, warranting parallels to current programs.

4 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 06, 2026

Across 41 SEC filings dated March 6, 2026, primarily 8-Ks, 10-Ks, and proxies from diverse sectors mislabeled as Consumer Staples, overarching themes include FY2025 revenue declines in 6/12 reporting companies averaging -6% YoY (Krispy Kreme -8.6%, IMXI -8%, Mammoth -2.9%, ArcelorMittal -1.7%), widening net losses in biotechs (PMV +32% to $77.7M) offset by narrowing in services (Mammoth -65% to $63.8M via SG&A -83%), and active M&A (KEEMO control stake, Kratos $353M Orbit buy, Monroe-HRZN merger). Forward-looking catalysts shine with PMV NDA Q1 2027 (34% ORR), Clover GAAP profit 2026, Honeywell Aerospace spin Q3 2026, and Monroe pro forma NII rising to $1.24 by 2030. Capital allocation trends favor buybacks (Lakeland doubled to $60M) and debt for repurchases (O'Reilly $850M notes), but dilution risks loom from offerings (Modular $12M at premium) and conversions (Velo3D notes). Portfolio-level patterns reveal cash pressures (PMV cash -38% to $113M, runway Q2 2027) and litigation (Monroe suits), implying selective opportunities in clinical/M&A plays amid broader weakness. Sector implications point to turnaround potential via divestitures (Mammoth $150M cash, liquidity $157M) but vigilance on delistings (UAMY) and impairments (Krispy $356M goodwill).

25 high priority 16 medium 41 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 06, 2026

Across 87 filings from S&P 500 Industrials and adjacent sectors (heavily skewed to financials/banks at ~30%, biotechs/pharma ~15%, with true industrials like shipping, aerospace sparse), sentiment is mixed with 40% positive, 45% mixed, 15% negative; aggregate net income trends show 12/20 banks/financials up YoY (avg +35%, range 23-75%) driven by NII growth (avg +15%) and M&A, but offset by impairments/merger costs. Revenue growth strong in growth names (e.g., 25-39% YoY in Guidewire, Pattern Group, Granite Ridge) but margins compressed avg -100bps in 8/15 reporting cos amid higher opex/R&D. Key developments include M&A acceleration (Kratos Orbit $353M, Day One $2.5B acq at 68% premium, Honeywell Aerospace spin Q3 2026), proxy season ramp (20+ AGMs April 2026), and biotech catalysts (PMV NDA Q1 2027). Portfolio-level: Industrials show cap alloc stability (dividends flat/up), insider conviction low-visibility but positive CEO comp at Alphabet/Stanley; risks from credit deterioration (NPLs up in 4 banks) and cash burns (PMV -38% cash). Implications: Tactical longs in M&A banks/industrials, caution biotechs, watch Q1 earnings for NIM trends.

56 high priority 31 medium 87 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 06, 2026

In the S&P 500 Energy intelligence stream, Cheniere Energy's 8-K highlights a strategic Senior Notes offering due 2036 and 2056 for debt refinancing, capex, and growth opportunities, carrying high materiality (8/10) amid neutral sentiment. Howard Hughes Holdings' 8-K sets the 2026 AGM for June 4 with a record date of April 6, adjusting proposal deadlines to March 17 due to a >30-day shift from 2025, with low materiality (4/10) and neutral sentiment. No period-over-period comparisons (YoY/QoQ revenue, margins, or operational metrics) were disclosed across filings, limiting trend visibility. Absent insider trading activity, forward-looking guidance focuses on Cheniere's conditional debt raise and Howard Hughes' governance catalysts. Capital allocation leans toward Cheniere's debt-funded reinvestment vs. Howard Hughes' shareholder engagement timeline. Sector implications point to financing maneuvers supporting energy infrastructure amid no evident portfolio-level growth or compression patterns. Actionable focus: monitor Cheniere's offering execution for leverage shifts and Howard Hughes' proposal deadlines for governance risks.

1 high priority 1 medium 2 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 06, 2026

Across 347 filings from S&P 500 Financials and related entities, overarching themes include mixed financial performance with 12/25 10-Ks showing revenue growth averaging +25% YoY (e.g., Cohen & Co +454%, Chime +31%) but 8/25 reporting net losses widening (avg +40%, e.g., PMV Pharma +32%), margin compression in 7/15 cases (avg -150bps), and heavy M&A/SPAC activity (15 deals, e.g., Monroe Capital merger, Spring Valley fusion). Capital allocation favors dividends/buybacks in 9 firms (e.g., MarketWise +25% dividend, Cohen $0.95 special), while biotech/pharma (10 filings) highlight clinical progress amid cash burns (runway into 2027-2028). Insider activity shows low conviction with few buys but CEO transitions in 12 cases signaling potential shifts. Forward guidance mixed: 6 raises (e.g., MarketWise FY26 billings $300M), 4 cuts/lowers, building catalysts like AGMs (April) and earnings. Portfolio trends: Financials NIM stable/expanding in banks (e.g., Republic +20bps), but impairments/delisting risks in 8 small caps; relative outperformers like Cohen vs laggards like BP (-16% profit). Implications: Tactical buys in growth financials/M&A, caution on cash-burn biotechs.

237 high priority 110 medium 347 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 06, 2026

Across 22 filings in the USA S&P 500 Technology stream (though spanning finance, biotech, banks, and limited pure tech like Salesforce/NVIDIA), overarching themes include mixed financial performance with revenue/NII growth via M&A or clinical progress offset by rising expenses, NPAs, and dilutions; 7/22 showed YoY net income/loss improvements averaging 15% (e.g., biotechs narrowing losses 8-39%). Period-over-period trends highlight revenue acceleration in select names (IRADIMED +14% YoY, Camden NII +53% YoY) but portfolio declines (Oxford -3.4% YoY) and stable margins/NIM (IRADIMED gross 77% flat, banks ~4%). Insider activity limited to Form 4s (GENCO May25-Feb26 changes) and ownership updates (dMY to Mar6), signaling neutral conviction; capital allocation favors stable distributions/dividends (Oxford $0.105/share, Camden $0.42/qtr flat). Forward-looking catalysts cluster in biotechs (Immuneering 1H26 data, mid-2026 Ph3; Adial cash to H2 2026). Portfolio implications: Bullish turnaround in clinical biotechs, caution on banks' credit quality deterioration and dilutions; tech filings (Salesforce/NVIDIA) neutral with org/comp tweaks signaling continuity amid FY27 revenue focus.

16 high priority 6 medium 22 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 06, 2026

Across 19 NASDAQ-100 related SEC filings from March 6, 2026, dominant themes include mixed financial performances in regional banks driven by mergers (e.g., First Community's Hometown acquisition completed Jan 23, 2026; Camden's Northway boosting NII +53% YoY), biotech firms narrowing net losses amid clinical progress (Immuneering's 64% OS rate vs 35% benchmark, Adial's -39% net loss improvement), and neutral capital market activities like debt shelf registrations (CIBC $20B) and offerings (CPKC $1.2B). Period-over-period trends show revenue growth in select names (IRADIMED +14% YoY, Altimmune +105% YoY) but expense pressures (G&A up across biotechs, noninterest expenses +38% at Camden), with ROE dips in banks (First Community -0.39pp, Camden -0.40pp). Positive catalysts cluster in biotech (Immuneering Phase 3 mid-2026, expanded data 1H2026), while tech filings highlight executive compensation alignment (Alphabet CEO $355M package, NVIDIA FY2027 variable plan). Portfolio-level patterns reveal bank M&A fueling asset growth (+20% Camden, +2% Muncy) but credit quality mixed (Muncy NPAs +18%), suggesting sector rotation opportunities into biotechs with extended cash runways (Immuneering to 2029). Overall, filings signal cautious optimism with 7/19 mixed sentiment, emphasizing monitoring Q1 2026 catalysts for alpha.

14 high priority 5 medium 19 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 06, 2026

Across 110 SEC filings from diverse US-listed firms (despite DJIA 30 focus, spanning banks, biotechs, SPACs, energy, and fintech), sentiment is predominantly mixed/neutral (70+ filings), with 25% positive on growth catalysts like revenue surges (avg +20-30% YoY in standouts like Grab, Via, Republic Bancorp) and clinical progress, but offset by cash burns, impairments, and exec churn. Period-over-period trends reveal banking sector resilience (e.g., NIM expansions in Republic +20bps, Northrim +NII 20%) amid rising NPLs (e.g., Home Bancorp 1.25% vs 0.50%), while biotechs show widened losses (PMV +32% YoY) but pipeline advances; energy firms mixed with Mammoth liquidity up to $158M post-divestitures. Capital allocation leans conservative (shelf registrations, buybacks like Dave $70M repurchase, Harley 10b5-1 plan), with SPACs/M&A active (ReserveOne, Vine Hill). Forward-looking catalysts cluster in Q1-Q2 2026 (PMV NDA, Nuvve BESS ops, Aptiv spin-off), signaling near-term volatility but alpha in undervalued growth names. Portfolio implication: Rotate to banks with NIM tailwinds and biotechs with derisked trials, hedge delisting/Nasdaq risks in small caps.

75 high priority 35 medium 110 total filings
· daily

US SEC Filings Daily Market Digest — March 06, 2026

Across 433 SEC filings dated March 6, 2026, for the period March 6, 2026, dominant themes include mixed 10-K results with revenue growth averaging +15% YoY in high-materiality filings (e.g., Chime +31%, Pattern Group +39%) offset by margin compression (-100 to -200 bps in 6/12 REITs/energy firms) and widened losses in biotech/REITs (e.g., Ares RE net loss doubled to $127M); M&A/SPAC activity surges with 15+ deals/announcements (e.g., Day One $2.5B acquisition, Quipt delisting post-arrangement); capital allocation favors dividends/buybacks (News Corp $1B program, MarketWise +25% dividend, 5 firms raised payouts); insider transitions neutral (e.g., Liberty CLO to advisor); delisting risks in 8 small caps (Traeger, Intensity regained but others flagged). Portfolio trends show REITs with NOI +12-21% but FFO drops (NewLake flat, Ares -82%), energy mixed (Granite production +28%, BP -12%), BDCs stable NAV/distributions. Forward guidance positive in 7/15 (MarketWise FY26 billings $300M, up from FY25 beat), bearish cuts in retail (Genesco FY27 sales flat). Implications: Opportunities in accretive M&A/guidance raises amid undervalued spin-offs; risks from delistings, covenant waivers (Nortech), impairments (Western Alliance $126M). Overall sentiment mixed (60% of 10-Ks), with action now on catalysts like March closings.

277 high priority 156 medium 433 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 06, 2026

Across 85 SEC filings from the S&P 500 Consumer Discretionary stream (broadly encompassing retail, automotive, hospitality, and adjacent sectors), overarching themes include mixed financial performance with 12/25 10-Ks showing YoY revenue growth averaging +18% (e.g., Chime +31%, Guidewire +25%) offset by declines in 8/25 averaging -15% (e.g., MarketWise -19.7%, Oxford Square portfolio -3.4%), margin compression in 10/20 reporting cos averaging -100bps amid expense growth, and robust capital returns via dividends (15 declarations, avg +10%) and buybacks (5 programs expanded/resumed). Critical developments feature accretive M&A (Chatham Lodging hotels at 10% cap rate adding 12% EBITDA, Kratos/Orbit $353M), spin-offs (Aptiv/Versigent by Apr 2026 with $1.7B dividend), and guidance raises (MarketWise FY26 billings to $300M, CFFO $50M). Portfolio-level patterns reveal hospitality strength (RevPAR +15% in acquisitions), subscription shifts to higher-ARPU (MarketWise ARPU $670), and bank-like efficiency gains (NII +15% avg in financial adjacents), signaling resilience in consumer spending pockets but caution on costs/delisting risks. Forward catalysts cluster in Apr-May 2026 (proxies, dividends, deal closes), positioning selective buys in undervalued growth names.

60 high priority 25 medium 85 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 06, 2026

Across 38 filings in the USA S&P 500 Healthcare intelligence stream (including tangential financials, biotechs, and providers), mixed sentiment dominates (15/38 filings), reflecting revenue/NII growth (avg 20% YoY in banks like Arrow +19.2%, Chime +31%) offset by rising expenses/losses (Chime net loss x40 to $1.01B, Jade +171% YoY) and asset quality slips (Flushing NPAs +25% YoY). Biotech standouts like Solid Biosciences ($240M raise, runway H1 2028), Jade ($336M cash post-$180M PIPE, Phase 1/2 data Q2 2026), and Absci (new CMO) signal pipeline conviction amid R&D surges. Healthcare provider Humana gears up for Apr 16 AGM with refreshed board (9/10 independent, age 73 retirement policy). Capital allocation shines with buyback expansions (Lakeland to $60M, Guidewire $148M repurchased), dividends (Broadridge $0.975/share), splits (HBIO 1:10 effective Mar 13), and financings (Core Scientific $500M loan to $1B accordion). Portfolio trends show NIM expansion (~+40bps avg in 7 banks to 3.6%), but NPAs rising in 4/6 banks (avg +18% YoY); April AGM cluster as key catalyst for governance votes. Implications: Favor growth biotechs/banks with strong liquidity, trim deteriorating asset quality names ahead of meetings.

27 high priority 11 medium 38 total filings
· daily

Global High-Priority Regulatory Events — March 06, 2026

Across 303 filings dated March 6, 2026, focused on critical US SEC events like bankruptcies, takeovers, and regulatory actions, overarching themes include mixed 10-K performances with 12/20 named companies showing revenue growth (avg +15% YoY) offset by margin compression (avg -100bps in 8/15) and impairments, robust SPAC/IPO activity (e.g., Lendbuzz 83% revenue CAGR, APEX $112M IPO), and frequent delisting risks (7 small caps below $1/share). Positive catalysts dominate financings (Allarity $20M notes, Dave $175M convertibles) and M&A (Quipt takeover, HCL acquisition), while bearish signals cluster in insolvencies (Reliance fraud, Cyient JV liquidation) and energy REIT declines (NewLake assets -2.5% YoY). Portfolio-level trends reveal BDCs/REITs with NAV dips (avg -3%) amid stable dividends, insider pledges/terminations signaling caution (Camlin promoter pledge +0.94%), and forward guidance mixed (BP upstream flat 2026, Monroe pro forma NII +18% to 2030). Sector rotations favor fintech/AI IPOs over legacy energy (BP sales flat YoY), with capital returns steady (dividend hikes in 5/15). Actionable now: Buy dip in growth SPACs, avoid insolvency-linked names.

303 high priority 303 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 06, 2026

A surge in SPAC IPO filings dominates the March 6, 2026, IPO pipeline with three blank check companies (Apogee, Patriot, ACP Holdings) registering standard $10 units and $11.50 warrants, signaling a potential SPAC market revival targeting tech sectors and generating up to $480M in combined proceeds. Northfield Bancorp's S-1 reveals a shrinking loan book at -4.1% YoY to $3.86B, driven by -9.1% multifamily decline (61% of portfolio), though offset by +24.0% construction and +14.1% home equity growth, amid mixed deposit market shares (9.64% in Staten Island vs 0.65% Brooklyn). An S-4 filing tied to Northfield Bancorp (CIK 0002115119) hints at merger activity with financial tags spanning 2022-2025 across loans and securities, lacking quantitative trends but covering credit quality segments. No forward-looking guidance or insider sales noted across filings, but sponsor founder shares (e.g., Apogee's 9.3M, Patriot's 5.75M) indicate strong alignment. Portfolio-level trends show SPACs as bullish outliers with positive sentiment vs Northfield's mixed, highlighting bifurcation between speculative vehicles and operating banks facing YoY contraction. Implications include near-term liquidity influx for de-SPAC hunts and caution on banking IPOs amid competition and loan softness.

5 high priority 5 total filings
· daily

US Earnings Financial Results SEC Filings — March 06, 2026

Across 102 SEC filings for FY2025/Q1 FY2026 financial results, mixed sentiment dominates (95/102 filings), reflecting resilient revenue growth in tech (e.g., Chime +31%, Guidewire +25%), banking (avg loan growth 10-20%), and energy (Granite Ridge +18%) but offset by widening losses from impairments, higher expenses, and margin compression in REITs/BDCs (avg NOI +10-20% but net losses up 10-50%). Period-over-period trends show YoY revenue growth in 60% of filers (median +12%) but operating margins mixed with compression in 40% (avg -100bps), driven by capex/debt rises; cash from ops improved in 55% (median +20%) amid cost controls. Banking outliers shine with NIM expansions (Republic Bancorp +20bps to 5.05%), while REITs face NOI declines (Ares same-store -2.1%); BDCs/SPACs highlight portfolio expansions but NAV drops. Capital allocation favors dividends/buybacks stability (e.g., Camden National flat $0.42/share), but debt rises signal leverage risks. Forward catalysts cluster around Q1 2026 earnings/AGMs (Apr-May), M&A closes (e.g., Hometown Jan 2026), and SPAC deadlines (May-Jun 2026). Implications: Tactical longs in high-ROE banks/tech, shorts on impaired REITs; portfolio tilt to NIM-expanders amid rate uncertainty.

102 high priority 102 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 06, 2026

Across 25 DEF 14A proxy statements filed around March 6, 2026, for April 2026 annual meetings, dominant themes include standard proposals for director elections (all companies), advisory say-on-pay votes (24/25), and auditor ratifications for FY2026 (25/25), with heavy representation from financials/banks (9/25 filings). Period-over-period data highlights record performances in outliers like Unity Bancorp (ROE 18.07%, NIM 4.52%) and Kirby Corp (revenues +3% YoY to $3.4B, EPS +16% to $6.33), contrasted by cost controls (Mobix auditor fees -19.5% YoY) and pay hikes (Boeing CEO +28% to $23.6M amid -3.8% stock drop). Sentiment skews neutral (18/25), with positives in AGNC (559% TSR since IPO vs 264% S&P Financials) and Unity, mixed in high-materiality cases like Boeing, Mobix (Nasdaq reverse split), CDT Equity (80% dilution risk), and Kirby. Portfolio-level trends show margin stability or strength in performers, high insider ownership in Seaboard (74.5%), and capital allocation via dividends (AGNC $15B cumulative). Market implications favor monitoring governance votes for comp alignment amid M&A (Tri Pointe, DataSea) and Nasdaq risks, with alpha in undervalued outperformers pre-meeting catalysts.

25 high priority 25 total filings
· daily

US Executive Officer Management Changes SEC — March 06, 2026

Across 49 SEC filings dated March 6, 2026, focused on USA executive and director changes, a surge in C-suite transitions dominates, with 18 CFO/CAO/accounting officer shifts (e.g., FTAI Aviation, GXO Logistics, PacBio), 15 board appointments/expansions (e.g., PROCEPT BioRobotics, Middleby, Korn Ferry), and 12 departures/resignations (e.g., BiomX CEO, Ashford Hospitality CFO, Planet 13 CAO), signaling portfolio-level leadership refresh amid neutral sentiment (70% neutral, 15% positive, 10% mixed/negative). No explicit YoY/QoQ financial trends emerge due to filing focus, but compensation enhancements in 8 firms (e.g., Workday CEO equity awards up to 547k PVUs, James River CEO incentives doubled to 150%/200%) indicate management retention efforts and conviction. Liberty Media ecosystem shows coordinated CLO transitions to advisor roles (3 filings), while small-caps like 374Water and Vicarious Surgical report terminations/salary cuts amid restructuring/delisting risks. Positive hires emphasize finance/audit expertise (e.g., GXO CFO with 30+ years), potentially bolstering margins/operations, but sudden exits raise governance flags. Implications: Bullish for firms adding proven talent (e.g., MIDD, KFY), bearish for abrupt CFO churn (avg materiality 7/10), with catalysts like annual meetings (May-Jun 2026) and transitions (Apr-Jan 2027) to monitor for stability.

49 high priority 49 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 06, 2026

The 51 filings in the USA Corporate Distress & Bankruptcy stream reveal a surge in listing compliance failures, with at least 10 companies (Traeger, Presurance Holdings, Offerpad, Jaguar Health, Beyond Meat, Iveda, Nerdy, Borealis Foods, United States Antimony, Spirit Aviation) cited for sub-$1.00 bid prices over 30 days, triggering 180-day cure periods often reliant on reverse stock splits approved in late 2025/early 2026. Debt restructurings and waivers dominate distressed signals (Nortech covenant waivers on Leverage Ratio/EBITDA, Gran Tierra 90% note exchange at higher 9.75% coupon), alongside impairments (Western Alliance $126.4M non-cash charge) and bankruptcy contexts (Spirit ongoing Ch.11 since Aug 2025). Positive counter-trends include sizable financings (Dave $175M conv notes with $70.5M buybacks, Core Scientific $500M loan expandable to $1B, Solid Biosciences $240M placement extending runway to H1 2028) and M&A (Day One $2.5B acquisition at 68% premium). No aggregate YoY/QoQ revenue/margin trends available across filings, but liquidity injections via $20M+ raises (Allarity, Honeywell up to $16B notes) signal aggressive survival tactics amid neutral-to-mixed sentiments (avg materiality 8/10). Portfolio implications: elevated short-term delisting/bankruptcy risks in small-caps, but select turnarounds via premium deals and debt extensions offer alpha for contrarians.

51 high priority 51 total filings
· daily

US SEC Trading Suspension Halt Orders — March 06, 2026

A cluster of 9 small-cap companies across diverse sectors (foods, health, tech, real estate, mining) disclosed 8-Ks on March 6, 2026, revealing NYSE/Nasdaq non-compliance notices primarily for sub-$1.00 average closing prices over 30 consecutive trading days, signaling acute portfolio-level distress in low-float names. Overarching theme: 8/9 filings cite bid price violations under rules like NYSE 802.01C or Nasdaq 5550(a)(2), with cure periods of 180 days or 6 months granted to most, but Jaguar Health (JAGX) faces immediate delisting risk due to prior reverse splits exceeding 250:1 ratio. No period-over-period financial trends provided across filings, but forward-looking plans emphasize reverse stock splits (approved in 5/9 cases) and appeals as remedies; sentiments skew negative/mixed with high materiality (avg 9/10). Critical implication: Potential mass delistings by Sep 2026 could drive shares to OTC markets, eroding liquidity and shareholder value. UAMY adds JV forward-looking upside amid delisting notice. Portfolio pattern: Small-cap vulnerability to penny stock thresholds amid challenging financial conditions (e.g., BRLS), highlighting short-term trading halts/delisting catalysts.

9 high priority 9 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 06, 2026

Across 49 SEC filings on March 6, 2026, focused on USA board room changes, the dominant theme is elevated C-suite turnover, particularly in finance roles with 15+ CFO/CAO transitions, appointments, or departures, amid neutral sentiment (avg materiality 6/10). Positive hires of experienced executives (e.g., ex-CFOs from Shockwave, Deloitte, Spirit AeroSystems) in 12 companies signal strategic refresh for growth/margins, while sudden terminations (e.g., Planet13 CAO, Midland CFO) raise stability concerns. No aggregate period-over-period financial trends disclosed (e.g., revenue YoY, margins QoQ absent), but compensation hikes (e.g., James River CEO STI to 150% base, Workday CEO 547k PVUs) and equity grants indicate management retention focus. Liberty ecosystem (3 filings) shows coordinated CLO transition to advisor role later 2026, neutral impact. Portfolio-level: Small/mid-caps dominate churn (30/49), suggesting governance evolution; watch Q2 2026 for post-transition execution as catalysts.

49 high priority 49 total filings
· daily

US Merger & Acquisition SEC Filings — March 06, 2026

The 12 filings reveal a surge in SPAC lifecycle events (7/12 filings), including IPOs raising $572M+ in trust proceeds (APEX $112M, Illumination $230M), non-redemption agreements to extend deadlines (Crown PropTech to March 2027), and promissory notes for operations (Artius II up to $1M), signaling robust M&A pipeline activity amid tight timelines. Completed M&A/divestitures dominate the rest (4/12), with accretive buys like Chatham Lodging's $92M hotel acquisition (RevPAR $116 vs prior sold $101, margins 42% vs 27%, +12% EBITDA) and Kratos' $353M Orbit deal, plus Albemarle's $670M asset sales for debt reduction; High Wire's $150k settlement clears $804k liabilities to enable takeover. Governance crises in Drugs Made In America entities (3 filings) highlight sponsor irregularities ($1.1M improper withdrawals post-IPO, no trust impact but CEO removals), contrasting positive sentiment (9/12 positive/neutral). No broad YoY/QoQ revenue trends due to transactional nature, but capital allocation leans toward accretive M&A/debt paydown vs dividends (Chatham +11% to $0.10/share). Portfolio-level: SPACs preserve ~$1B+ in trusts for deals; M&A valuations attractive ($156k/room Chatham, $13.73/share Orbit). Implications: Heightened M&A catalysts Q1-Q2 2026, watch SPAC redemptions and Drugs resolutions for volatility.

12 high priority 12 total filings